Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.60    -0.025 (-4.00%)
Bid:
0.55
Ask:
0.65
Spread: 0.10 (18.182%)
Market Cap: £2.72m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director's Notification

24 Dec 2010 09:06

RNS Number : 5892Y
Physiomics PLC
24 December 2010
 



Physiomics plc

 

(the "Company")

 

Director's Notification

 

In accordance with AIM Rule 17, the following information relating to Mark Chadwick, Chief Executive Officer of the Company, is required to be disclosed under

sub-paragraphs (iii) to (viii) of paragraph (g) of Schedule Two to the AIM Rules for Companies:

 

Mark Chadwick is also a director of EnviroGene Limited ("EnviroGene") which, on 23rd December 2010, appointed Roger G. Hale and Robert N. Lewis of PriceWaterhouseCoopers LLP ("PWC") as administrators. EnviroGene, which specialises in providing molecular diagnosis solutions to the water and oil and gas industries, had struggled with trading in the current financial climate. Following a substantial restructuring to save costs and a failed attempt at raising funds to continue operations, the decision was taken, in discussions with EnviroGene's major creditor, to put the company into administration. At the last balance sheet date of 20 December 2010 (taken from unaudited management accounts) the Net Asset Value of EnviroGene was approximately £316,378, excluding £790,000 of convertible loan notes. The majority of the loan notes were held by a single major investor.

 

Mark had, at all times, ensured Physiomics was fully aware of the working capital position of EnviroGene and the challenges EnviroGene was facing in the current climate.

 

Enquiries:

 

Physiomics plc

Dr Paul Harper, Non-Executive Chairman 

+44 (0)1865 784980

 

WH Ireland Limited

Katy Mitchell

+44 (0) 161 832 2174

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDNGMMZZLDKGGZG
Date   Source Headline
13th Dec 20217:00 amRNSMerck Contracts
23rd Nov 20213:30 pmRNSResult of AGM
12th Nov 202112:00 pmRNSConference presentation
12th Nov 202112:00 pmRNSConference presentation
27th Oct 20211:00 pmRNSPosting of Annual Report and AGM Notice
22nd Oct 20217:00 amRNSContract awards
30th Sep 20213:00 pmRNSResults Presentation and DoseMeRx Update
30th Sep 20217:00 amRNSFinal Results
16th Sep 20212:45 pmRNSPARNTER study recruits first patient
15th Sep 20217:00 amRNSNotice of Results and Investor Presentation
31st Aug 20217:00 amRNSPhysiomics hires Head of Business Development
19th Jul 20217:00 amRNSPhysiomics expands technical team
29th Jun 20219:16 amRNSDirector Dealing
21st May 20214:40 pmRNSDirector Dealing
21st May 20217:00 amRNSContract awards
14th May 20217:00 amRNSContract award
11th May 20217:00 amRNSContract award
10th May 20217:00 amRNSTrading update
9th Apr 20212:00 pmRNSConference presentation
22nd Mar 20217:00 amRNSDirector/PDMR Shareholding
12th Mar 20217:00 amRNSPresentation and Q&A on Company's Interim Results
4th Mar 20217:00 amRNSInterim Results Presentation
2nd Mar 202110:12 amRNSIssue of Options
1st Mar 20217:00 amRNSInterim Results
15th Feb 20217:00 amRNSValiRx Agreement
18th Dec 20207:00 amRNSHolding(s) in Company
17th Dec 20202:00 pmRNSPartnership with TRHC's DoseMeRx®
17th Dec 20207:00 amRNSMerck Contracts
14th Dec 20207:00 amRNSApproval of NIHR-funded PARTNER study
17th Nov 202012:59 pmRNSResult of AGM
22nd Oct 20208:30 amRNSPosting of Annual Report and AGM Notice
22nd Oct 20207:00 amRNSPosting of Annual Report and AGM Notice
16th Oct 20207:00 amRNSContract awards
6th Oct 20209:00 amRNSPresentation and Q&A on Company’s Final Results
30th Sep 20207:00 amRNSFinal Results and Notice of AGM
25th Sep 20207:00 amRNSFull year results release date and shareholder Q&A
11th Sep 20207:00 amRNSHolding(s) in Company
12th Aug 20207:00 amRNSDirector Dealing
5th Aug 20201:00 pmRNSIssue of Equity
5th Aug 20207:00 amRNSIssue of Equity and Director Dealing
4th Aug 20207:00 amRNSTrading update
31st Jul 20207:00 amRNSPhysiomics awarded contract by Astellas Pharma Inc
22nd Jul 202011:45 amRNSShare Price Movement
17th Jul 20209:00 amRNSPrice Monitoring Extension
6th Jul 202010:00 amRNSDirector dealing
30th Jun 20202:30 pmRNSContract award and update
22nd Jun 20207:00 amRNSConference presentation
10th Jun 20201:00 pmRNSHolding(s) in Company
27th May 20207:00 amRNSFundraise
15th May 20201:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.